THE MINISTER OF NDUSTRY (SHRI J. VENGAL RAO) : (a) and (b) The Kelkar Committee recommended drugs to be incuded in Category II for price control by adopting the following exclusion criteria:-

(i) Exclude those drugs which are not produced in India, provided that the consumption is not significant either now or in the near future.

(ii) To exclude those drugs the turn over of which has been less than rupees fifty lakhs in 1986.

(iii) To exclude all new drugs for which p·ocess of manufacture were deve'oped indigenously from the price control list at least for the first five years.

(iv) To exclude those life-saving drugs and pharmaceutical p·oducts whose availability is far more important than the price. As the nature of demand is such that it is required less frequently but its non-availability is fatal. The notable examp'es of such categories are sera and vaccines.

(v) Exclude those pharmaceutical products of drugs where the domestic production structure is so competitive that there is little possibility that the consumer will be over-charged compared to the cost of production.

भारतीय तेल निगम के अधिकारियों द्वारा दवाइयों के जाली बिलों के आधार पर राशि वसूल किया जाना

4583. **श्री सुनील कुमार पटनायक** : क्या पेट्रोलियम और प्राकृतिक गैस मंत्री यह बताने की कृपा करेंगे कि :

(क) क्या यह सच है कि भारतीय तेल निगम के कैलाश बिल्डिंग, 26 कस्तूरबा गांधी मार्ग, नई दिल्ली स्थित पाइपलाइन प्रभाग के कार्यालय में क्लर्क ग्रेड से ऊपर के अधिकारियों द्वारा दवाइयों के झूठे चिकित्सा खर्च प्रतिपूर्ति बिल देकर प्रति अधिकारी प्रति मास हजारों रुपए वसूल किए जा रहे हैं जो साल में लाखों रुपए तक पहुंच जाते हैं ;

(ख) यदि हां, तो क्या सरकार इस संबंध में केन्द्रीय जांच ब्यूरो से कोई जांच कराने का विचार रखती है ;

(ग) उपर्युक्त भाग (क) में उल्लिखित प्रत्येक अधिकारी का नाम और पदनाम क्या है और गत तीन वर्षों के दौरान उनमें से प्रत्येक अधिकारी द्वारा चिकित्सा प्रतिपूर्ति के रूप में कितनी-कितनी राशि प्राप्त की गई ;

(घ) क्या जाली चिकित्सा बिल प्रस्तुत करके इस प्रकार भारी राशि को वसूलने पर अंकुश लगाए जाने का कोई प्रस्ताव सरकार के विचाराधीन है ; और

(ङ) यदि हां, तो इस संबंध में ब्यौरा क्या है और यदि नहीं, तो उसके क्या कारण हैं ?

पेट्रोलियम और प्राकृतिक गैस मंत्रालय के राज्य मंत्री (श्री ब्रह्म दत्त) : (क) जी, नहीं। (ख) से (ङ.) प्रश्न नहीं उठता।

All India Estimates of Retail Sales of Drugs

4584. PROF. C. LAKSHMANNA: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3283 given in the Rajya Sabha on 22nd August, 1988 and state:

(a) whether it is a fact that his Ministry is subscribing to ORG;

(b) if so, what was the all India estimates of retail sales of Isoxuprine, Fluclonolone Acetonide, Polymixin-B Sulphate, Glipizide, Phenformin HCl and Chloropropamide based on records maintained by the 650 chemists;

(c) what are the reasons for not providing the prices of leader brand of each drug before the announcement of DPCO, 1987, their present prices sand the percentage change in each case;

(d) what are the grounds on which his Ministry found it difficult to provide prices of seven formulations terming it as voluminous;

(e) whether his Ministry is monitoring the price increases ;

(f) if so, what are the reasons for which Parliament is not being informed about price increase which is of public importance; and

(g) what are the basis on which each of these drugs have been price decontrolled?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO) : (a) The Ministry is subscribing to a number of publications including ORG.

(b) Sales turnover is not monitored.

(c) and (d) The referred drugs are in generic name and being marketed by a number of companies as single ingredient, in combinations, in different forms and packs.

(e) and (f) Monitoring of prices of decontrolled drugs is being done and Parliament is being provided with the information asked for specifically through replies to questions wherever the same is avilable.

(g) The referred bulk drugs have been price decontrolled, as recommended by Kelkar Committee.

Prices of Dexona Tablets and Dexamethasone Eye Drop

4585. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUSTRY be pleased to state:

(a) what is the approved price of Dexona Tablets and Dexamethasone eye preparations of the same company and when were these prices approved;

(b) whether it is a fact that these preparations are beng sold without price approval;